[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356147-105":59,"doc-detail-356147-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","alternative-splicing-rewires-breast-cancer-and-opens-therapeutic-avenues","Alternative splicing rewires breast cancer and opens therapeutic avenues","","Breast cancer exhibits profound molecular and clinical heterogeneity, reflected in diverse subtypes, metastatic patterns, and treatment responses. Emerging evidence indicates this complexity arises not only from genetic and epigenetic alterations but also from post-transcriptional regulation, especially alternative splicing (AS), which expands proteomic diversity and functional versatility. AS produces multiple mRNA isoforms from a single gene, shaping oncogenic processes such as migration, metabolic reprogramming, immune evasion, and therapy resistance. High-throughput sequencing and bioinformatics enable mapping AS landscapes, supporting clinical translation through molecular subtyping, prognostic biomarkers, and splice-switching therapies. Challenges remain, including tumor heterogeneity and limited splicing specificity, which must be addressed to enable precision oncology via AS modulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/alternative-splicing-rewires-breast-cancer-and-opens-therapeutic-avenues/356147/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/alternative-splicing-rewires-breast-cancer-and-opens-therapeutic-avenues/356147.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does alternative splicing (AS) contribute to breast cancer heterogeneity?","Question",{"text":112,"@type":113},"AS generates multiple mRNA isoforms from single genes, producing diverse protein isoforms and thereby enriching transcriptomic and proteomic diversity. This expanded diversity supports oncogenic progression and contributes to differing clinical and molecular behaviors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which breast cancer processes are influenced by dysregulated AS?",{"text":117,"@type":113},"Dysregulated AS can affect cell migration, metabolic reprogramming, immune evasion, oncogenic transformation, cancer progression, and therapy resistance. It can also inactivate tumor suppressors or promote oncogene expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical applications does the review emphasize for AS findings?",{"text":121,"@type":113},"The review evaluates translational potential of AS signatures for molecular subtyping, prognostic biomarkers, and splice-switching therapeutics. It also highlights the need to overcome challenges related to tumor heterogeneity and splicing specificity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356147,1791177724,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Jin et al. Cell Communication and Signaling (2026) 24:464  \n[https://doi.org/10.1186/s12964-026-03017-5](https://doi.org/10.1186/s12964-026-03017-5)  \nCell Communication and Signaling  \nREVIEW Open Access  \nAlternative splicing rewires breast cancer and opens therapeutic avenues  \nYuhan Jin1†, Yiran Liang1†, Mahsa Maghsoudy Kasvaei2 and Qifeng Yang1,3,4*  \nAbstract  \nBreast cancer exhibits profound molecular and clinical heterogeneity, manifested through diverse subtypes, metastatic patterns, and therapeutic responses. Emerging evidence underscores that this complexity stems not merely from genetic and epigenetic aberrations but also from post-transcriptional regulatory mechanisms, particularly alternative splicing (AS), which amplifies proteomic diversity and functional versatility. AS generates multiple mRNA isoforms from a single gene, directly influencing oncogenic processes including cell migration, metabolic reprogramming, immune evasion, and therapy resistance. Recent advances in high-throughput sequencing and bioinformatics have enabled systematic mapping of AS landscapes in breast cancer. This review delineates the mechanistic underpinnings of AS regulation and synthesizes cutting-edge discoveries in AS-drivenoncogenic pathways. We further evaluate the translational potential of AS signatures in clinical applications, such as molecular subtyping, prognostic biomarkers, and splice-switching therapeutics. Finally, we address persisting challenges, including tumor heterogeneity and the lack of splicing specificity, that must be overcome to harness AS modulation as a precision oncology strategy.  \nKeywords Breast cancer, Alternative splicing, Splicing factor, Biomarker, Therapeutic target  \nBackground  \nBreast cancer remains the most frequently diagnosed malignant tumor among women worldwide, accounting for 32% of all female malignancies and causing 14% of cancer-related deaths, ranking second in female cancer mortality [1]. Despite advances in early detection  \n†Yuhan Jin and Yiran Liang contributed equally to this work.  \n*Correspondence:  \nQifeng Yang  \n[qifengy_sdu@163.com](qifengy_sdu@163.com)  \n1Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, Shandong 250012, P. R. China  \n2School of Medicine, Shandong University, Jinan, Shandong  \n250012, P. R. China  \n3Biological Resource Center, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P. R. China  \n4Research Institute of Breast Cancer, Shandong University, Jinan, Shandong 250012, P. R. China  \nand systemic therapies, clinical outcomes vary significantly, underscoring the profound heterogeneity of the disease [2]. This heterogeneity manifests at multiple levels, including molecular, histopathological, and clinical aspects, which are deeply rooted in complex genetic and epigenetic regulatory mechanisms, collectively influencing tumor progression, metastatic potential, and response to treatment [3]. Among these diverse mechanisms, AS has emerged as a crucial regulatory layer that significantly enriches the transcriptomic and proteomic diversity of breast cancer, thereby amplifying its heterogeneity and driving disease progression.  \nIn eukaryotic cells, precursor messenger RNAs (premRNAs) undergo post-transcriptional splicing, a process where introns are removed and exons are ligated to form mature mRNAs [4]. For most multi-exonic genes, the selective combination of exons often occurs during splicing, a process known as AS, enabling a single gene  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have perm","cbCaidEWhtD2YJYC","https://ap.wps.com/l/cbCaidEWhtD2YJYC","pdf",3584501,21,"English","# Abstract\n# Background\n## Breast cancer heterogeneity and clinical impact\n## AS as a key post-transcriptional regulatory layer\n# Rationale and objectives of the review","[{\"question\":\"How does alternative splicing (AS) contribute to breast cancer heterogeneity?\",\"answer\":\"AS generates multiple mRNA isoforms from single genes, producing diverse protein isoforms and thereby enriching transcriptomic and proteomic diversity. This expanded diversity supports oncogenic progression and contributes to differing clinical and molecular behaviors.\"},{\"question\":\"Which breast cancer processes are influenced by dysregulated AS?\",\"answer\":\"Dysregulated AS can affect cell migration, metabolic reprogramming, immune evasion, oncogenic transformation, cancer progression, and therapy resistance. It can also inactivate tumor suppressors or promote oncogene expression.\"},{\"question\":\"What clinical applications does the review emphasize for AS findings?\",\"answer\":\"The review evaluates translational potential of AS signatures for molecular subtyping, prognostic biomarkers, and splice-switching therapeutics. It also highlights the need to overcome challenges related to tumor heterogeneity and splicing specificity.\"}]","Alternative splicing rewires breast cancer and opens therapeutic avenues | PDF",1790123669,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/425ea7f0bf2b42d3a3d672facbeb0e5f.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e1ed2b717fb3cb6bf8962ff53dbc64c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bdffd09639a520f8e53fc424c37219e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30e967e1ed39afdd9df0b11dc28c2016.webp",980,1306]